FDA Grants Priority Review of Biologics License Application for Atacicept in IgA Nephropathy

Atacicept, a dual BAFF/APRIL inhibitor, granted priority review for IgA nephropathy on the strength of trials showing substantial, sustained proteinuria reduction with stabilization of kidney function compared with placebo.